A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
NCT06846671 · CaDAnCe-302 Phase 3Recruiting
- Lead sponsor
- BeOne Medicines (Industry)
- Enrollment
- 250 (estimated)
- Start date
- 10 Apr 2025
- Primary completion
- 15 May 2028 (estimated)
- Study completion
- 14 Feb 2030
- Last update posted
- 28 Sep 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- None
- Arms
- 2
Interventions
- Tacabrutideg Drug
- Bendamustine Drug
- Idelalisib Drug
- Rituximab Drug
- Venetoclax Drug
Conditions and primary outcome
- CLL
- Chronic Lymphocytic Leukemia
Primary outcome
Progression-Free Survival (PFS) by Independent Review Committee (IRC) (Approximately 36 Months)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT06846671.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT06846671 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.